Rating Change
Morgan Stanley analysts reiterated a Overweight rating on CME Group Inc. (NASDAQ:CME) on July 23, 2026.
Rating Change Morgan Stanley analysts reiterated a Overweight rating on CME Group Inc. (NASDAQ:CME) on July 23, 2026. Market Context CME Group Inc.

Morgan Stanley analysts reiterated a Overweight rating on CME Group Inc. (NASDAQ:CME) on July 23, 2026.
CME Group Inc. operates in the Financial Services sector. The stock currently trades at $254.32 with a market capitalization of $98.2B. The stock has declined 12.1% over the past 52 weeks.
Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for CME Group Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 6 Buy, 2 Hold, 2 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 23, 2026 | Morgan Stanley | Overweight | N/A |
| Jul 23, 2026 | B of A Securities | Underperform | N/A |
| Jul 23, 2026 | JP Morgan | Underweight | N/A |
| Jul 15, 2026 | Piper Sandler | Overweight | N/A |
| Jul 10, 2026 | Morgan Stanley | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View CME Stock Page
A Overweight rating from Morgan Stanley reflects the analyst's outlook on CME Group Inc. (NASDAQ:CME). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CME forecast page.
Current market data
NASDAQ · CME
$269.80
Up: +$2.59 · +0.97%
Live quote updated
Keep reading